Share This Page
Drugs in ATC Class L01EN
✉ Email this page to a colleague
Drugs in ATC Class: L01EN - Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
| Tradename | Generic Name |
|---|---|
| BALVERSA | erdafitinib |
| PEMAZYRE | pemigatinib |
| TRUSELTIQ | infigratinib phosphate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class L01EN (FGFR tyrosine kinase inhibitors): exclusivity clocks, Orange Book presence, and generic and biosimilar entry risks
FGFR tyrosine kinase inhibitors (TKIs) sit in a high-cost, high-intensity IP zone. The near-term market dynamics are driven by (1) label expansion across oncology settings that supports longer net sales duration, (2) payer-driven sequencing strategies, and (3) faster-than-traditional competitive ramp in cohorts where multiple FGFR TKIs have meaningful efficacy. The patent landscape is dominated by a layered model: early composition-of-matter (C-of-M) plus later patent families covering specific polymorphs, salts, solid forms, dose regimens, combination therapy (method-of-use), and manufacturing/process details. Market entry risk for generics is less about direct “easy copy” and more about whether a challenger can find a regulatory and legal pathway that avoids blocking method-of-use and formulation families while also fitting the branded product’s formulation and dosing.
What FGFR tyrosine kinase inhibitors are in ATC L01EN and how do they drive market share?
ATC L01EN is the oncology therapeutic class covering FGFR-targeting TKIs. The competitive core for commercial and IP analysis is led by branded FGFR inhibitors that have oncology label coverage, with rosters often including:
- Pemigatinib (oral FGFR1-3 inhibitor)
- Infigratinib (oral FGFR1-3 inhibitor)
- Futibatinib (oral irreversible pan-FGFR inhibitor)
- Derazantinib (development-stage in many markets; IP and commercialization status varies by geography)
- Others with narrower footprint depending on market-by-market approvals and ATC coding practice
Market dynamics are shaped by how these drugs compete within the same histology and line-of-therapy clusters:
- Cholangiocarcinoma (CCA): fast-moving sequencing, often post-gemcitabine/cisplatin or post-chemotherapy settings, with subsequent line expansion in select geographies.
- Non-small cell lung cancer (NSCLC) and urothelial cancer (UC): driven by FGFR alterations and biomarker-based patient selection; label scope and claims language affect whether method-of-use patents block combinations.
Commercial exposure varies by country and reimbursement. In the US and major EU markets, the largest revenue exposure typically comes from established branded products with continuing label activity and payer reimbursement.
How do biomarkers and line of therapy determine revenue duration?
FGFR TKIs are biomarker-defined. That means “market size” is not only the prevalence of FGFR alterations but also:
- the proportion of patients tested and tested accurately,
- the willingness of payers to reimburse without broad confirmatory testing,
- and the adoption of sequencing protocols that place FGFR TKIs at specific lines.
These factors influence patent value by determining how long branded dosing regimens stay entrenched.
What patents protect FGFR tyrosine kinase inhibitors across CCA and other FGFR-altered cancers?
Featured answer: The patent estate is typically built from four layers: C-of-M, formulation/solid state, method-of-use (treatment regimens and combinations), and manufacturing/process patents.
Because FGFR TKIs share the same target class but differ in chemical scaffolds and dosing regimens, patent protection often diverges at the “later layer” level even when C-of-M families have overlapping filing years.
Layer 1: Composition of matter (core molecules, salts, stereochemistry, polymorphs)
For each branded FGFR TKI, the earliest families usually cover:
- the active compound or close chemical variants,
- pharmaceutically acceptable salts,
- and sometimes stereochemical configurations.
These patents usually expire later than formulation and method-of-use families but can be extended by regulatory data exclusivity and, in some jurisdictions, patent-term adjustment mechanisms.
Layer 2: Formulation, solid state, and manufacturing
Common later claims include:
- specific tablet/capsule compositions,
- defined particle size ranges or polymorphs,
- process steps that improve stability or bioavailability,
- and dissolution or stability method controls.
This layer matters for generic “design-around.” A challenger may be able to satisfy bioequivalence without copying the exact formulation, but if the branded product’s approved dosage form aligns with later solid-form claims, entry can be blocked.
Layer 3: Method-of-use patents (monotherapy, lines, combinations)
Method-of-use families can cover:
- monotherapy in specified FGFR-altered tumors,
- first-line or subsequent-line treatment positions,
- combination regimens with chemotherapy, immunotherapy, or anti-EGFR/VEGF partners,
- and patient selection criteria using biomarkers.
These patents often outlast formulation patents and can be the legal gating factor for launch timing in US Paragraph IV strategies if a challenger’s proposed label or intended use falls within the method claims.
Layer 4: Manufacturing and intermediates
Process patents covering key intermediates, purification steps, or solvent systems can add additional barriers. Even where they do not directly block an ANDA, they can support injunction risk in parallel litigation.
Which companies hold the patent estates for major FGFR TKIs (pemigatinib, infigratinib, futibatinib)?
Featured answer: Ownership typically splits along two tracks: the original innovator (molecule + clinical development) and associated formulation/CMC licensors or assignees for specific solid-form or process improvements. In the US, the Orange Book listing is usually tied to the US NDA holder, while the patent estate may be distributed across affiliates and research entities.
For business decisions, the operational question is not who invented the molecule, but:
- who owns the specific Orange Book-listed patents for each NDA,
- and which assignees are named in litigation and enforcement.
Practical IP consequence: in Paragraph IV cases, assignee identity affects:
- litigation leverage,
- settlement posture,
- and the probability of obtaining licensing agreements that allow “at-risk” launch.
What is the Orange Book status for FGFR TKI branded products and how many patents are listed per NDA?
Featured answer: Orange Book listings for branded FGFR TKIs are commonly multi-patent per NDA, with clusters in:
- drug substance (C-of-M),
- drug product (formulation/solid state),
- and sometimes use patents if method claims are tied to approved indications.
The number of listed patents is usually high enough that a challenger must identify which are vulnerable and which are blocking.
How do use patents change generic launch risk?
If the Orange Book lists use patents tied to approved indications, challengers can face risk of:
- forfeiture or settlement at a negotiated “carve-out” date,
- or exclusion from the approved label until litigation ends.
In practice, launch timing may depend on whether the challenger carves out indications, proposed dosing regimens, or patient populations.
When do major FGFR TKIs lose exclusivity in the US: patent expiry vs FDA exclusivity?
Featured answer: Launch freedom is governed by both:
- patent expiration (including enforceable Orange Book patents), and
- regulatory exclusivity (data exclusivity and any orphan exclusivity where applicable).
Because FGFR TKIs often enter oncology markets with accelerated or breakthrough designations, regulatory status can create layered exclusivity even after patent clocks start.
How to model a launch window for generic/authorized competitors
A typical US timeline model for a given NDA uses:
- Earliest patent expiration (excluding those with active injunction risk)
- Latest enforceable blocking patent expiration
- Potential FDA regulatory exclusivity end date
- Risk of pediatric exclusivity or other extensions (where applicable)
- Settlement-triggered “effective launch date” in any Paragraph IV case
What patent expirations for FGFR TKIs matter most for Paragraph IV challenges?
Featured answer: The most litigation-relevant expirations are those of Orange Book-listed patents with the latest end dates and those in the drug substance and drug product categories that support enforceability.
Method-of-use patents are often the second highest-impact because challengers cannot always avoid them via label carve-outs without reducing market attractiveness.
What are the typical Paragraph IV strategy patterns?
Common patterns for challengers in FGFR TKIs include:
- targeting the earliest expiring patents to accelerate at-risk filings,
- identifying which patents are likely to face invalidity or non-infringement arguments,
- and using label carve-outs to avoid method-of-use coverage.
Settlement is common where the probability-weighted litigation cost plus sales upside favors a mid-point launch.
What patent litigation affects FGFR TKIs: likely outcomes and settlement dynamics?
Featured answer: FGFR TKI litigation tends to produce early settlement windows because Orange Book estates are crowded and method-of-use patents increase injunction leverage.
How settlement agreements shape real-world entry
When a Paragraph IV suit settles, the result is typically one of:
- delayed launch with a stated entry date,
- licensing with royalties,
- or partial label entry with carved indications.
These agreements often focus on:
- the specific dosage form,
- the dosing schedule,
- and the approved indications that map to method-of-use claim scope.
What generic entry risks exist for FGFR TKIs: formulation, solid state, and method-of-use barriers?
Featured answer: The principal risks for generics are not merely chemical similarity. They are:
- solid-state/formulation patent coverage tied to approved dosage forms, and
- method-of-use patents that constrain the challenger’s label.
Formulation and solid-state design-around
If Orange Book drug product patents cover:
- polymorph,
- defined composition ratios,
- or stability-driven process parameters, then the challenger’s “bioequivalence-only” approach can fail in infringement.
Method-of-use and label carve-out
Even if the generic can avoid direct infringement of drug product patents, method-of-use claims can still block meaningful launch unless:
- the carve-out stays outside claim scope, and
- the carved label still yields acceptable market access.
How does futibatinib compare with pemigatinib and infigratinib on patent duration and entry timing?
Featured answer: Futibatinib’s irreversible mechanism and distinct scaffold typically produce a different patent map, but the market gating factors remain similar: later formulation and method-of-use patents can delay competitive entry even after earlier molecule claims expire.
Comparison dimensions that drive entry timing
- Crowded Orange Book listings: more patents increase the “blocking set.”
- Presence of use patents: increases settlement probability and label carve-out constraints.
- Solid-state breadth: limits substitution of formulation variants without legal exposure.
- Biomarker-driven clinical label scope: affects method-of-use claim relevance and carve-out value.
What formulations are protected by FGFR TKI patents (tablets/capsules) and how do CMC claims affect generics?
Featured answer: The protected formulation space usually includes:
- specific tablet/capsule compositions,
- excipient selections affecting dissolution,
- and stable solid forms tied to manufacturing processes.
Dose regimen patents and infringement
If dosing regimens (dose escalation, cycle timing, combination schedules) are claimed as part of method-of-use patents, generics may be able to ship but not legally market at the desired label.
How strong is the patent estate for FGFR TKIs: what drives enforceability and litigation leverage?
Featured answer: Patent strength in FGFR TKIs is typically highest where:
- Orange Book lists the latest expiry patents,
- claims are broad enough to cover the marketed dosing and formulation,
- and infringement maps cleanly to approved label instructions.
Key enforceability drivers:
- claim construction likelihood,
- prosecution history estoppel risk,
- and whether later patents are vulnerable to obviousness-type challenges.
What makes some FGFR TKI families more resilient
- multiple dependent claims covering different polymorphs or salt forms,
- process claims that capture manufacturing route even if formulation is adjusted,
- and method-of-use patents that align with common guideline-adjacent regimens.
Biosimilar risk: do FGFR TKIs face biologics-style pathways?
FGFR TKIs are small molecules. Biosimilars do not apply. Competitive entry risks are routed through:
- ANDA-style generic pathways for small-molecule duplicates, and
- Section 505(b)(2) routes for new formulations or dosing claims.
So the “biosimilar” category is not a direct analogue for FGFR TKIs.
What regulatory pathways do generics use for FGFR TKIs and how does that affect IP leverage?
Featured answer: For oral small-molecule FGFR TKIs, challengers typically use ANDA if the generic is an exact duplicate of the drug product and the method-of-use carve-out strategy is viable. For changed formulation/dosing, 505(b)(2) can be used, but it does not remove patent risk and can still trigger Paragraph IV type disputes when Orange Book-listed patents are asserted.
Orphan exclusivity and accelerated approval effects
If a product has orphan exclusivity and accelerated approvals that lead to later label expansions, the regulatory clock and patent clock can misalign. That can change the settlement economics because the challenger can obtain a partial path sooner in certain geographies.
Which markets outside the US have the biggest impact on FGFR TKI competitive dynamics?
Featured answer: US and EU are the main value pools for FGFR TKIs, but patent enforceability and generic launch timing depend on:
- the scope of granted patents in each jurisdiction,
- whether relevant patents are validated in-country,
- and local regulatory rules for generic approval and patent linkage.
EU and UK
European enforcement can create broader injunction leverage where national validations exist. If the same family is validated across multiple countries, coordinated litigation can raise the cost of “multi-country at-risk” strategies.
Key takeaways
- FGFR TKIs in ATC L01EN face a stacked IP estate: molecule patents plus formulation/CMC and method-of-use patents that commonly extend litigation leverage beyond early C-of-M expiry.
- Market exclusivity duration depends on both regulatory exclusivity and the latest enforceable Orange Book-listed patents, with method-of-use and drug product patents often driving settlement and label carve-out outcomes.
- Generic entry risk is highest where Orange Book includes multiple blocking patents across drug substance, drug product, and use categories.
- Competitive timing is less about chemical duplication and more about whether challengers can legally and commercially market under the approved dosing and indications without infringing later patent families.
FAQs
- How do label carve-outs for generic FGFR TKIs typically work when Orange Book lists method-of-use patents?
- What types of solid-state or polymorph patents most often block generic entry for oral oncology TKIs?
- How do settlement dates in US Paragraph IV suits translate into real-world market entry schedules for FGFR TKIs?
- What is the practical difference between ANDA and 505(b)(2) strategies for competing FGFR TKIs with crowded patent lists?
- Which IP family categories (drug substance vs drug product vs method-of-use) most strongly predict injunction risk for FGFR TKIs?
References (APA)
- US Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- US Food and Drug Administration. (n.d.). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency. (n.d.). Medicines. EMA. https://www.ema.europa.eu/en/medicines
More… ↓
